{"disease":{"id":"advanced-malignant-tumor","name":"advanced malignant tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07480733","title":"Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":480,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT05779163","title":"A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":468,"lead_sponsor_name":"Nanjing Leads Biolabs Co.,Ltd","has_results":false},{"nct_id":"NCT06764771","title":"A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":437,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06877650","title":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":436,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT06770881","title":"JSKN033 in Chinese Subjects with Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":430,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT07287995","title":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT05728541","title":"Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":367,"lead_sponsor_name":"CSPC Ouyi Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06115642","title":"A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT04225117","title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":329,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT06464055","title":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04708210","title":"Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":256,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07391644","title":"A Study of JSKN027 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT04145622","title":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT04956926","title":"Clinical Study of JS201 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":244,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT04969887","title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":240,"lead_sponsor_name":"Olivia Newton-John Cancer Research Institute","has_results":false},{"nct_id":"NCT05198817","title":"A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03611868","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT07292402","title":"JSKN022 in Subjects With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02500797","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02721732","title":"Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07459920","title":"Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":156,"lead_sponsor_name":"National Cancer Institute, Naples","has_results":false},{"nct_id":"NCT05214482","title":"A Study of AK112 in Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT05229497","title":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":154,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT06962553","title":"Nurses' Competence and Role in Survival Prediction and Prognostic Communication","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":152,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT07293754","title":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Repertoire Immune Medicines","has_results":false},{"nct_id":"NCT06154343","title":"A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT06592417","title":"To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT05396391","title":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"SUNHO（China）BioPharmaceutical CO., Ltd.","has_results":false},{"nct_id":"NCT05396339","title":"A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"SUNHO（China）BioPharmaceutical CO., Ltd.","has_results":false},{"nct_id":"NCT05089461","title":"A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":120,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT05103358","title":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Aadi Bioscience, Inc.","has_results":false},{"nct_id":"NCT04222413","title":"Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05277454","title":"Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":113,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT07368127","title":"A Study of TPD3310 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.","has_results":false},{"nct_id":"NCT07050641","title":"Phase I/II Study of SCTB39-1 in Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT06717750","title":"A Study of CSCJC3456 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","has_results":false},{"nct_id":"NCT06059508","title":"Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06022250","title":"The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":98,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT07038005","title":"A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Shenyang Sunshine Pharmaceutical Co., LTD.","has_results":false},{"nct_id":"NCT04954456","title":"A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04328506","title":"Bioequivalency Study of CM082 Tablet in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"AnewPharma","has_results":false},{"nct_id":"NCT06571422","title":"Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":93,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06380309","title":"A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":89,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT05767060","title":"BAT7104 Injection in Patients With Advanced Malignant Tumors.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Bio-Thera Solutions","has_results":false},{"nct_id":"NCT02159989","title":"Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}